Eledon pharmaceuticals receives fda clearance of ind application to evaluate tegoprubart in iga nephropathy

Irvine, calif., sept. 06, 2022 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn), today announced that the u.s. food and drug administration (fda) has cleared the company's investigational new drug (ind) application to evaluate tegoprubart for the treatment of iga nephropathy (igan).
ELDN Ratings Summary
ELDN Quant Ranking